In a closely watched patent battle, the U.S. Supreme Court on Thursday unanimously ruled against California-based drugmaker Amgen, affirming a lower court's decision that Amgen's French rival Sanofi didn't infringe on patents on a cholesterol-lowering antibody drug. The long-running feud ...